{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:09:09Z","timestamp":1783152549036,"version":"3.54.6"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T00:00:00Z","timestamp":1416268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s13365-014-0303-1","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T12:03:37Z","timestamp":1416571417000},"page":"623-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy"],"prefix":"10.1007","volume":"21","author":[{"given":"Salim","family":"Chahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,18]]},"reference":[{"key":"303_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/03946320140270S102","volume":"27","author":"A Armuzzi","year":"2014","unstructured":"Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Cimaz R (2014) anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol 27:11\u201332","journal-title":"Int J Immunopathol Pharmacol"},{"key":"303_CR2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/11537510-000000000-00000","volume":"33","author":"JR Berger","year":"2010","unstructured":"Berger JR (2010) Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 33:969\u2013983","journal-title":"Drug Saf"},{"key":"303_CR3","first-page":"495","volume":"12","author":"JR Berger","year":"2012","unstructured":"Berger JR, Khalili K (2012) The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med 12:495\u2013503","journal-title":"Discov Med"},{"key":"303_CR4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","volume":"4","author":"JR Berger","year":"1998","unstructured":"Berger JR, Pall L, Lanska D, Whiteman M (1998) Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 4:59\u201368","journal-title":"J Neurovirol"},{"key":"303_CR5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","volume":"74","author":"JR Berger","year":"2013","unstructured":"Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ (2013) JC virus antibody status underestimates infection rates. Ann Neurol 74:84\u201390","journal-title":"Ann Neurol"},{"key":"303_CR6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:883\u2013897","journal-title":"Nat Rev Drug Discov"},{"key":"303_CR7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","volume":"2","author":"BR Brooks","year":"1984","unstructured":"Brooks BR, Walker DL (1984) Progressive multifocal leukoencephalopathy. Neurol Clin 2:299\u2013313","journal-title":"Neurol Clin"},{"key":"303_CR8","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","volume":"56","author":"LH Calabrese","year":"2007","unstructured":"Calabrese LH, Molloy ES, Huang D, Ransohoff RM (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 56:2116\u20132128","journal-title":"Arthritis Rheum"},{"key":"303_CR9","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834\u20134840","journal-title":"Blood"},{"key":"303_CR10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68:1156\u20131164","journal-title":"Arch Neurol"},{"key":"303_CR11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180:63\u201370","journal-title":"J Neuroimmunol"},{"key":"303_CR12","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","volume":"65","author":"M Pilar Martin del","year":"2008","unstructured":"del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stuve O (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 65:1596\u20131603","journal-title":"Arch Neurol"},{"key":"303_CR13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","volume":"368","author":"U Ermis","year":"2013","unstructured":"Ermis U, Weis J, Schulz JB (2013) PML in a patient treated with fumaric acid. N Engl J Med 368:1657\u20131658","journal-title":"N Engl J Med"},{"key":"303_CR14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, Investigators CS (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087\u20131097","journal-title":"N Engl J Med"},{"key":"303_CR15","doi-asserted-by":"crossref","unstructured":"Fredericks C, Kvam K, Bear J, Crabtree G, Josephson S (2014). A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus","DOI":"10.1177\/0961203314524292"},{"key":"303_CR16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, Investigators DS (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098\u20131107","journal-title":"N Engl J Med"},{"key":"303_CR17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00282-999-0183-7","volume":"41","author":"H Gonzalez","year":"1999","unstructured":"Gonzalez H, Bolgert F, Camporo P, Leblond V (1999) Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 41:183\u2013186","journal-title":"Hematol Cell Ther"},{"key":"303_CR18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","volume":"121","author":"FH Gordon","year":"2001","unstructured":"Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn\u2019s disease. Gastroenterology 121:268\u2013274","journal-title":"Gastroenterology"},{"key":"303_CR19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","volume":"16","author":"FH Gordon","year":"2002","unstructured":"Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE (2002) A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 16:699\u2013705","journal-title":"Aliment Pharmacol Ther"},{"key":"303_CR20","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","volume":"290","author":"KB Gordon","year":"2003","unstructured":"Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A (2003) Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290:3073\u20133080","journal-title":"JAMA"},{"issue":"3","key":"303_CR21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen L, Berman M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68(3):295\u2013303","journal-title":"Ann Neurol"},{"key":"303_CR22","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","volume":"175","author":"AB Gottlieb","year":"2005","unstructured":"Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG (2005) TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175:2721\u20132729","journal-title":"J Immunol"},{"key":"303_CR23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","volume":"9","author":"HM Gurcan","year":"2009","unstructured":"Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9:10\u201325","journal-title":"Int Immunopharmacol"},{"key":"303_CR24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","volume":"364","author":"MJ Hanaway","year":"2011","unstructured":"Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R, Holman J, Group IS (2011) Alemtuzumab induction in renal transplantation. N Engl J Med 364:1909\u20131919","journal-title":"N Engl J Med"},{"key":"303_CR25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676\u2013688","journal-title":"N Engl J Med"},{"key":"303_CR26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/imt.14.7","volume":"6","author":"CM Hersh","year":"2014","unstructured":"Hersh CM, Cohen JA (2014) Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Immunotherapy 6:249\u2013259","journal-title":"Immunotherapy"},{"key":"303_CR27","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616\u20135623","journal-title":"J Clin Oncol"},{"key":"303_CR28","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1212\/WNL.41.11.1733","volume":"41","author":"RC Holman","year":"1991","unstructured":"Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC (1991) Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 41:1733\u20131736","journal-title":"Neurology"},{"key":"303_CR29","doi-asserted-by":"crossref","unstructured":"Isidoro L, Pires P, Rito L, Cordeiro G (2014) Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep","DOI":"10.1136\/bcr-2013-201781"},{"key":"303_CR30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.27189","volume":"62","author":"AM Jacobi","year":"2010","unstructured":"Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A (2010) Effect of long-term belimumab treatment on B cells in systemic lupus erythmatosus: extension of a phase II, double-blink, placebo-controlled, dose-ranging study. Arthritis Rheum 62:201\u2013210","journal-title":"Arthritis Rheum"},{"key":"303_CR31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, Group FS (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401","journal-title":"N Engl J Med"},{"key":"303_CR32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","volume":"74","author":"MJ Keating","year":"1989","unstructured":"Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74:19\u201325","journal-title":"Blood"},{"key":"303_CR33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369\u2013374","journal-title":"N Engl J Med"},{"key":"303_CR34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clim.2011.04.006","volume":"142","author":"L Klotz","year":"2012","unstructured":"Klotz L, Meuth SG, Wiendl H (2012) Immune mechanisms of new therapeutic strategies in multiple sclerosis-a focus on alemtuzumab. Clin Immunol 142:25\u201330","journal-title":"Clin Immunol"},{"key":"303_CR35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","volume":"71","author":"WA Knowles","year":"2003","unstructured":"Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115\u2013123","journal-title":"J Med Virol"},{"key":"303_CR36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jaad.2010.05.033","volume":"65","author":"N Kothary","year":"2011","unstructured":"Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G (2011) Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 65:546\u2013551","journal-title":"J Am Acad Dermatol"},{"key":"303_CR37","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","volume":"71","author":"M Krumbholz","year":"2008","unstructured":"Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E (2008) Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71:1350\u20131354","journal-title":"Neurology"},{"key":"303_CR38","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/art.27687","volume":"62","author":"D Kumar","year":"2010","unstructured":"Kumar D, Bouldin TW, Berger RG (2010) A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 62:3191\u20133195","journal-title":"Arthritis Rheum"},{"key":"303_CR39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375\u2013381","journal-title":"N Engl J Med"},{"key":"303_CR40","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2005.09.007","volume":"27","author":"RG Langley","year":"2005","unstructured":"Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB (2005) Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 27:1317\u20131328","journal-title":"Clin Ther"},{"key":"303_CR41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613\u2013620","journal-title":"Arthritis Rheum"},{"key":"303_CR42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","volume":"57","author":"P Lee","year":"2013","unstructured":"Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M (2013) A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57:141\u2013146","journal-title":"J Clin Virol"},{"key":"303_CR43","first-page":"239","volume":"33","author":"S Lejniece","year":"2011","unstructured":"Lejniece S, Murovska M, Chapenko S, Breiksa B, Jaunmuktane Z, Feldmane L, Ziedina I, Gomez-Roman J, Garcia-Cabeza M, Lejnieks A (2011) Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient. Exp Oncol 33:239\u2013241","journal-title":"Exp Oncol"},{"key":"303_CR44","first-page":"1121","volume":"158","author":"S Leonard","year":"2002","unstructured":"Leonard S, Hulin C, Anxionnat R, Grignon Y, Taillandier L, Vespignani H (2002) Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia. Rev Neurol (Paris) 158:1121\u20131123","journal-title":"Rev Neurol (Paris)"},{"key":"303_CR45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.det.2004.03.015","volume":"22","author":"CL Leonardi","year":"2004","unstructured":"Leonardi CL (2004) Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 22:427\u2013435, ix","journal-title":"Dermatol Clin"},{"key":"303_CR46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2007.11.007","volume":"194","author":"RL Lindberg","year":"2008","unstructured":"Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 194:153\u2013164","journal-title":"J Neuroimmunol"},{"key":"303_CR47","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ni1275","volume":"6","author":"AD Luster","year":"2005","unstructured":"Luster AD, Alon R, von Andrian UH (2005) Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 6:1182\u20131190","journal-title":"Nat Immunol"},{"issue":"Suppl 2","key":"303_CR48","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar549","volume":"4","author":"RN Maini","year":"2002","unstructured":"Maini RN, Feldmann M (2002) How does infliximab work in rheumatoid arthritis? Arthritis Res 4(Suppl 2):S22\u2013S28","journal-title":"Arthritis Res"},{"key":"303_CR49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","volume":"43","author":"SI Martin","year":"2006","unstructured":"Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43:16\u201324","journal-title":"Clin Infect Dis"},{"key":"303_CR50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jmv.21710","volume":"82","author":"A Matos","year":"2010","unstructured":"Matos A, Duque V, Beato S, da Silva JP, Major E, Melico-Silvestre A (2010) Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 82:494\u2013504","journal-title":"J Med Virol"},{"key":"303_CR51","first-page":"14","volume":"84","author":"A Menter","year":"2009","unstructured":"Menter A (2009) The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 84:14\u201324","journal-title":"Cutis"},{"key":"303_CR52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2008.07.006","volume":"8","author":"ES Molloy","year":"2008","unstructured":"Molloy ES, Calabrese LH (2008) Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 8:144\u2013146","journal-title":"Autoimmun Rev"},{"key":"303_CR53","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","volume":"64","author":"ES Molloy","year":"2012","unstructured":"Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64:3043\u20133051","journal-title":"Arthritis Rheum"},{"key":"303_CR54","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1017\/S031716710001547X","volume":"39","author":"PW O\u2019Connor","year":"2012","unstructured":"O\u2019Connor PW (2012) Natalizumab risk stratification: role of a two- step anti-JCV antibody assay. Can J Neurol Sci 39:670\u2013675","journal-title":"Can J Neurol Sci"},{"key":"303_CR55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jbspin.2011.11.002","volume":"79","author":"E Palazzo","year":"2012","unstructured":"Palazzo E, Yahia SA (2012) Progressive multifocal leukoencephalopathy in autoimmune diseases. Jt Bone Spine 79:351\u2013355","journal-title":"Jt Bone Spine"},{"key":"303_CR56","doi-asserted-by":"crossref","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML. Ann Neurol","DOI":"10.1002\/ana.24286"},{"key":"303_CR57","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"303_CR58","unstructured":"Putzki N, Clifford DB, Bischof D, Moore A, Weinshenker BG, Freedman MS (2014) Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab. Presentation at ECTRIMS 2014"},{"key":"303_CR59","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","volume":"17","author":"JT Ransom","year":"1995","unstructured":"Ransom JT (1995) Mechanism of action of mycophenolate mofetil. Ther Drug Monit 17:681\u2013684","journal-title":"Ther Drug Monit"},{"key":"303_CR60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/10428190290006297","volume":"43","author":"M Saumoy","year":"2002","unstructured":"Saumoy M, Castells G, Escoda L, Mares R, Richart C, Ugarriza A (2002) Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 43:433\u2013436","journal-title":"Leuk Lymphoma"},{"key":"303_CR61","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/QAD.0000000000000201","volume":"28","author":"T Schneider-Hohendorf","year":"2014","unstructured":"Schneider-Hohendorf T, Philipp K, Husstedt IW, Wiendl H, Schwab N (2014) Specific loss of cellular L-selectin on CD4+ T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. AIDS 28:793\u2013795","journal-title":"AIDS"},{"issue":"10","key":"303_CR62","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","volume":"81","author":"N Schwab","year":"2013","unstructured":"Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, G\u00f6bel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejf\u00e1r A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, K\u00fcmpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H (2013) L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 81(10):865\u2013871","journal-title":"Neurology"},{"key":"303_CR63","first-page":"79","volume":"7","author":"T Siddiqi","year":"2014","unstructured":"Siddiqi T, Thomas SH, Chen R (2014) Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharmgenomics Pers Med 7:79\u201385","journal-title":"Pharmgenomics Pers Med"},{"key":"303_CR64","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS Sorensen","year":"2012","unstructured":"Sorensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18:143\u2013152","journal-title":"Mult Scler"},{"key":"303_CR65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1083\/jcb.201207175","volume":"199","author":"L Steinman","year":"2012","unstructured":"Steinman L (2012) The discovery of natalizumab, a potent therapeutic for multiple sclerosis. J Cell Biol 199:413\u2013416","journal-title":"J Cell Biol"},{"key":"303_CR66","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1046\/j.1365-2133.2001.04220.x","volume":"144","author":"TJ Stoof","year":"2001","unstructured":"Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM (2001) The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 144:1114\u20131120","journal-title":"Br J Dermatol"},{"key":"303_CR67","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","volume":"63","author":"O Stuve","year":"2006","unstructured":"Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand\u2019Maison F, Hemmer B, Monson NL, Racke MK (2006a) Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63:1383\u20131387","journal-title":"Arch Neurol"},{"key":"303_CR68","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","volume":"59","author":"O Stuve","year":"2006","unstructured":"Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK (2006b) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743\u2013747","journal-title":"Ann Neurol"},{"key":"303_CR69","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMc1300283","volume":"368","author":"MT Sweetser","year":"2013","unstructured":"Sweetser MT, Dawson KT, Bozic C (2013) Manufacturer\u2019s response to case reports of PML. N Engl J Med 368:1659\u20131661","journal-title":"N Engl J Med"},{"key":"303_CR70","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1523-1747.2003.12605.x","volume":"121","author":"F Treumer","year":"2003","unstructured":"Treumer F, Zhu K, Glaser R, Mrowietz U (2003) Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Investig Dermatol 121:1383\u20131388","journal-title":"J Investig Dermatol"},{"key":"303_CR71","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353:362\u2013368","journal-title":"N Engl J Med"},{"key":"303_CR72","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","volume":"368","author":"BW Oosten van","year":"2013","unstructured":"van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP (2013) PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 368:1658\u20131659","journal-title":"N Engl J Med"},{"key":"303_CR73","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","volume":"76","author":"P Vermersch","year":"2011","unstructured":"Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, Bozic C, Richman S (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697\u20131704","journal-title":"Neurology"},{"key":"303_CR74","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1358\/dot.2009.45.7.1384878","volume":"45","author":"MC Villarroel","year":"2009","unstructured":"Villarroel MC, Hidalgo M, Jimeno A (2009) Mycophenolate mofetil: an update. Drugs Today (Barc) 45:521\u2013532","journal-title":"Drugs Today (Barc)"},{"key":"303_CR75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJMe020157","volume":"348","author":"UH Andrian von","year":"2003","unstructured":"von Andrian UH, Engelhardt B (2003) Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 348:68\u201372","journal-title":"N Engl J Med"},{"key":"303_CR76","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clim.2004.06.001","volume":"113","author":"Y Vugmeyster","year":"2004","unstructured":"Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, Lee E, Howell K, Bodary S, Dummer W, Krueger JG (2004) Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 113:38\u201346","journal-title":"Clin Immunol"},{"key":"303_CR77","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.healun.2008.12.010","volume":"28","author":"J Waggoner","year":"2009","unstructured":"Waggoner J, Martinu T, Palmer SM (2009) Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 28:395\u2013398","journal-title":"J Heart Lung Transplant"},{"key":"303_CR78","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3109\/10428194.2012.676170","volume":"53","author":"ND Wagner-Johnston","year":"2012","unstructured":"Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR (2012) Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 53:2283\u20132286","journal-title":"Leuk Lymphoma"},{"key":"303_CR79","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","volume":"67","author":"C Warnke","year":"2010","unstructured":"Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stuve O (2010) Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 67:923\u2013930","journal-title":"Arch Neurol"},{"issue":"3","key":"303_CR80","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ncl.2008.03.007","volume":"26","author":"T Weber","year":"2008","unstructured":"Weber T (2008) Progressive multifocal leukoencephalopathy. Neurol Clin 26(3):833\u2013854","journal-title":"Neurol Clin"},{"key":"303_CR81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","volume":"3","author":"F Zaheer","year":"2012","unstructured":"Zaheer F, Berger JR (2012) Treatment related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf 3:227\u2013239","journal-title":"Ther Adv Drug Saf"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-014-0303-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-014-0303-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-014-0303-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T11:19:04Z","timestamp":1689679144000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-014-0303-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,18]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s13365-014-0303-1","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,18]]}}}